This is risky business. Only invest what you can afford to lose.
Followers | 0 |
Posts | 1,505 |
Boards Moderated | 0 |
Alias Born | 02/27/2012 |
Twitter Profile: | Temporarily Unavailable |
Follow on Twitter: | Follow @ Temporarily Unavailable |
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
VYCO is my favorite kind of organic, word of mouth, nice steady gainer, with solid DD:
http://a.eqcdn.com/harbingerresearch/media/b767cf61ff1d00bcf70bf414fab946a5.pdf
VYCO up 33%, tight spread, L2 looks great. This has been showing signs of quiet accumulation by some heavy hitters for weeks now. The DD is what makes this an INVESTMENT not just a PLAY:
http://a.eqcdn.com/harbingerresearch/media/b767cf61ff1d00bcf70bf414fab946a5.pdf
I've been doing some DD into the float. Lot of inside holding. Some institutional. I have a few more questions I'm trying to nail down, then I'll put something definitive in the IBOX. One thing for certain, I have not found anything to worry about so far.
VYCO up 33%, tight spread, L2 looks great. The DD is what makes this an INVESTMENT not just a PLAY:
http://a.eqcdn.com/harbingerresearch/media/b767cf61ff1d00bcf70bf414fab946a5.pdf
VYCO is waking up! +33%, .019 x .02. Read this, you will be glad you did:
http://a.eqcdn.com/harbingerresearch/media/b767cf61ff1d00bcf70bf414fab946a5.pdf
VOLUME ALERT! Gonna keep my eye on this
VYCO is a long's pipe dream, a true undiscovered gem. A little volume is a great thing, but sometimes you can learn alot about a stock by how it behaves on slow days. VYCO holders actually hold. We're in this as a team to win this
Bid support looks better. Only 2 mm's to .022
VYCO has strong patent protection, FDA clearance for NoraVision and ViewSite, and little competition.
The Company has a very strong patent portfolio with 30 granted patents and 30 patents pending, providing it with significant IP protection and creating strong barriers to entry by would-be competitors.
More patent details here:http://investorshub.advfn.com/boards/read_msg.aspx?message_id=76489668
FDA and regulatory: http://ir.vycormedical.com/FDA_and_Regulatory
NovaVision's VRT is the only FDA 510(k) cleared medical device that is used to restore visual field loss that results from neurological trauma.
VYCO's NovaVision technology is the only FDA cleared treatment that restores vision lost by victims of stroke and traumatic brain injury.
Vycor NovaVision product offering is the first real, tested, proven treatment for a type of vision loss which the medical community has considered untreatable for over a hundred years. NovaVision literally restores sight to the blind. VYCO has generated a legitimate medical breakthrough.
"NovaVision provides a home-based treatment of vision rehabilitation after stroke or brain injury called Vision Restoration Therapy (VRTâ„¢). VRT is an FDA-cleared, patented, non-invasive medical device that enhances visual functions in patients with impairments due to stroke, surgical intervention, and traumatic brain injury (TBI). "
"70% of cases patients using NovaVision's VRT system over a three to six month period experience significant recovery in at least one functional outcome. In many cases this recovery is enough to restore lost abilities such as reading, avoiding unseen objects while walking, or in some cases even driving a car."
"Stroke and traumatic brain injury (TBI) victims are almost always told by their doctors that vision loss causedby neurological brain damage is permanent and irreversible; these doctors have been taught this "fact" since early in their careers, and they mostly accept it as a fact, without question. However, according to six Company-sponsored studies and fourteen independent studies, conducted over a period of 15 years, this is not a fact at all. It is instead a previously-valid medical conclusion based on old data and technology - it is not based on current research. We believe the new data regarding recently-developed technology (i.e. NovaVision's VRT and NeET) have clearly shown that vision loss can be at least partially restored in most cases..."
Read up on the science and research here, including 15 years of research and 20 clinical studies: http://www.novavision.com/clinical-studies
Every year, 795,000 victims in the US alone suffer a stroke. http://www.cdc.gov/stroke/facts.htm
Looks like some more people have stuck their nose in that good VYCO DD, no? ;-D
Nice to come back from lunch and have your wish granted ;-D
You did mention wanting to see more support at the bid right? ;-D
Check it out! People smell a bargain at .017 for sure
Wouldn't take much to push to .02 , that's for sure. I wouldn't mind seeing that spread close up some either, but I think recent history shows that the buying and holding definitely outweighs any flighty daytraders. The DD here is just so sweet. Longs know what we are holding here. Give this time to mature into that 10xs upside that the potential points to
It's consistent with the pattern of low level accumulation we've seen over the last several weeks. Some big players quietly adding over the long haul here who have sussed out the DD and like what they see.
" VYCO ViewSite Helps Neurosurgeons Address "Inoperable" Cases and Improves Outcomes The transparent ViewSite Brain Access System (VBAS) dramatically reduces the damage caused by "retractors" that surgeons now use to reach sub-surface areas of the brain. It also provides these surgeons with superior visibility during surgical procedures. The net effect of this is improved clinical outcomes, shorter surgeries, and shorter recovery times; in some cases this product's superior attributes have allowed brain surgeons to successfully perform surgeries that would have otherwise been considered inoperable. The VBAS is protected by a strong patent portfolio, and we believe its clinical superiority and cost savings will lead it to become the de facto standard in surgical devices for neurosurgery over the next few years."
Nice little chunk of volume to start the day. Would definitely like to see VYCO getting the market attention the DD deserves
Yessir! Love seeing that ask at 2's
VYCO sitting in green pastures again, BABY!
$1B+ Market Opportunity - "First Real Treatment for Stroke-Related Vision Loss Vycor's NovaVision helps victims of stroke and traumatic-brain injury permanently regain a key portion of lost vision-field. This is the first treatment for what has been considered a permanent and irreversible condition, and is backed by a strong scientific team, 15 years of research and 20 clinical studies. It is FDA 510(k) cleared, has a strong patent portfolio, and addresses a very large market in the United States, Europe, and around the world. Although we believe it will take NovaVision several years to penetrate a big percentage of this market, its multi-billion dollar size makes this product line a potential blockbuster for Vycor."
"The Company Should Enter Hyper-growth During the Next Two to Three Years Vycor's ViewSite is already making good inroads into the relatively small neurosurgery market, both in the U.S. and overseas, and we expect sales to grow robustly beginning in early 2013. However, we are most excited about the long-term potential of the NovaVision subsidiary, as its products have no real competition and address a global market that could be up to $20B in size."
Up and at 'em VYCO fanatics! Would be great to see some action early on here today ;)
You can add the next sentence from the report as well:
Good point. This is not a daytrader play at the moment by any stretch of the imagination. Lots of penny plays here on IHUB are gamblers wet dreams, with no real need or interest in solid fundamentals, pop and drops where all that matters is volume. VYCO is a solid integrous package. I really don't enjoy risking it all on a roll of the dice. That's why the solid DD here has me feeling secure in a long position.
Another quiet day
Slow day today for VYCO. As the executive leadership continues to implement further market penetration for NovaVision and ViewSite technologies, the continued upward trend of increasing revenues will not fail to garner the market attention that equal substantial upside for VYCO shareholders, imo
VYCO's NovaVision technology is the only FDA cleared treatment that restores vision lost by victims of stroke and traumatic brain injury.
Vycor NovaVision product offering is the first real, tested, proven treatment for a type of vision loss which the medical community has considered untreatable for over a hundred years. NovaVision literally restores sight to the blind. VYCO has generated a legitimate medical breakthrough.
"NovaVision provides a home-based treatment of vision rehabilitation after stroke or brain injury called Vision Restoration Therapy (VRTâ„¢). VRT is an FDA-cleared, patented, non-invasive medical device that enhances visual functions in patients with impairments due to stroke, surgical intervention, and traumatic brain injury (TBI). "
"70% of cases patients using NovaVision's VRT system over a three to six month period experience significant recovery in at least one functional outcome. In many cases this recovery is enough to restore lost abilities such as reading, avoiding unseen objects while walking, or in some cases even driving a car."
"Stroke and traumatic brain injury (TBI) victims are almost always told by their doctors that vision loss causedby neurological brain damage is permanent and irreversible; these doctors have been taught this "fact" since early in their careers, and they mostly accept it as a fact, without question. However, according to six Company-sponsored studies and fourteen independent studies, conducted over a period of 15 years, this is not a fact at all. It is instead a previously-valid medical conclusion based on old data and technology - it is not based on current research. We believe the new data regarding recently-developed technology (i.e. NovaVision's VRT and NeET) have clearly shown that vision loss can be at least partially restored in most cases..."
Read up on the science and research here, including 15 years of research and 20 clinical studies: http://www.novavision.com/clinical-studies
Every year, 795,000 victims in the US alone suffer a stroke. http://www.cdc.gov/stroke/facts.htm
Lunch hour done. Lets see what the afternoon holds.
That would definitely fit the trend so far: "Revenue up 198% Over First Quarter 2011; Vycor Medical Division Revenue up 222% Over 2011, NovaVision Division up 145%; Net Loss Reduced"
http://finance.yahoo.com/news/vycor-medical-inc-reports-first-130000889.html
The first quarter ended March 31, 2012. The 2nd quarter should be ending this month. But there is a grace period, as I understand it, between the end of the quarter and when the financials actually might be publicly released for VYCO to maintain its status as a fully reporting public company
Yes, the depth of the DD connected with VYCO is almost an embarassment of richness. Just a matter of time for this to light up imo
VYCO CEO Coviello has served in executive leadership for previous medical device company's with a combined total of $350MM in sales. You cannot underestimate the importance of the depth of the leadership bench when setting forecast figures for a company at VYCO's stage. Coviello is really like the clinch nail in a laundry list of reasons that have tipped my analysis to long for VYCO
VYCO story is so compelling: http://player.vimeo.com/video/39903199
VYCO is quite undervalued at this level. Can't think of another ticker at this pps with 200% revenue increases, FDA approved exclusively patented vision loss treatment, international distributor network, broad approval from the medical community and already used in 3000 medical procedures. The fundamentals here are very persuasive.